Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other financing activities (2016 - 2025)

Historic Other financing activities for Theravance Biopharma (TBPH) over the last 11 years, with Q3 2025 value amounting to $678000.0.

  • Theravance Biopharma's Other financing activities rose 7078.09% to $678000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 252.83%. This contributed to the annual value of $2.7 million for FY2024, which is 636.0% up from last year.
  • Per Theravance Biopharma's latest filing, its Other financing activities stood at $678000.0 for Q3 2025, which was up 7078.09% from $503000.0 recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Other financing activities peaked at $5.6 million during Q1 2021, and registered a low of $347000.0 during Q2 2022.
  • In the last 5 years, Theravance Biopharma's Other financing activities had a median value of $622500.0 in 2022 and averaged $1.0 million.
  • As far as peak fluctuations go, Theravance Biopharma's Other financing activities soared by 13161.09% in 2021, and later plummeted by 7411.05% in 2022.
  • Quarter analysis of 5 years shows Theravance Biopharma's Other financing activities stood at $455000.0 in 2021, then soared by 45.49% to $662000.0 in 2022, then dropped by 21.75% to $518000.0 in 2023, then rose by 1.93% to $528000.0 in 2024, then rose by 28.41% to $678000.0 in 2025.
  • Its Other financing activities stands at $678000.0 for Q3 2025, versus $503000.0 for Q2 2025 and $874000.0 for Q1 2025.